What is Lagevrio (molnupiravir) for?
Buy Lagevrio (molnupiravir). Lagevrio (molnupiravir) is a medicine for treating mild-to-moderate COVID-19. It is for adults who have tested positive for SARS-CoV-2 and have a risk factor for severe illness.
This medicine has been given ‘conditional approval’. This means more evidence is needed to confirm its effectiveness.
It comes in capsule form, with each capsule containing 200 mg molnupiravir.
How does Lagevrio (molnupiravir) work?
Lagevrio is an antiviral drug that stops SARS-CoV-2 from multiplying. It changes the virus’s RNA, making it hard for the virus to grow in the body.
This medicine may help people with COVID-19 avoid hospitalization and feel better faster.
Where has Lagevrio (molnupiravir) been approved?
Lagevrio (molnupiravir) has been approved for treating mild-to-moderate COVID-19 by:
- The Medicines and Healthcare products Regulatory Agency (MHRA), UK on November 4, 2021.
- The European Medicines Agency (EMA) on November 19, 2021.
- The Food and Drug Administration (FDA), USA on December 23, 2021.
- The Therapeutic Goods Administration (TGA), Australia under provisional approval on January 20, 2022.
This medicine may also be approved in other regions. If you have questions about its approval in a specific country, contact our support team.
How is Lagevrio (molnupiravir) taken?
The standard dosage is:
- Four 200 mg capsules (800 mg), taken by mouth (orally) every 12 hours for 5 days
Swallow the capsules whole. You can take them with or without food.
It’s crucial not to miss or skip doses of Lagevrio:
- If you forget to take a dose within 10 hours of the usual time, take it as soon as possible and then take the next one at the usual time.
- If you forget to take a dose by more than 10 hours, skip the missed dose and take the next one at the usual time.
- Do not take a double dose to make up for a missed dose.
For more details on dosage and administration, see the official prescribing information in our references section.
Note: Please consult with your treating doctor for personalized dosing.
Are there any known adverse reactions or side effects of Lagevrio (molnupiravir)?
Common adverse reactions
The most common side effects (≥10% of patients) include:
- Diarrhoea
- Nausea
- Feeling dizzy
- Headache
Use in a specific population
Lagevrio is not recommended for pregnant women. It may harm the unborn baby. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice. If you can become pregnant, use effective birth control during treatment and for 4 days after.
It’s not recommended to breast-feed during treatment and for 4 days after the last dose. It’s not known if Lagevrio gets into breast milk and will be passed to the baby. If you are breast-feeding or planning to, tell your doctor before taking this medicine.
For a full list of side effects and adverse reactions, refer to the official prescribing information.